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Abstract
Background: Non-smoking, having a normal weight and increased levels of physical activity are perhaps
the three key factors for preventing cardiovascular disease (CVD). However, the relative effects of these
factors on healthy longevity have not been well described. We aimed to calculate and compare the effects
of non-smoking, normal weight and physical activity in middle-aged populations on life expectancy with and
without cardiovascular disease.
Methods: Using multi-state life tables and data from the Framingham Heart Study (n = 4634) we
calculated the effects of three heart healthy behaviours among populations aged 50 years and over on life
expectancy with and without cardiovascular disease. For the life table calculations, we used hazard ratios
for 3 transitions (No CVD to CVD, no CVD to death, and CVD to death) by health behaviour category,
and adjusted for age, sex, and potential confounders.
Results: High levels of physical activity, never smoking (men), and normal weight were each associated
with 20-40% lower risks of developing CVD as compared to low physical activity, current smoking and
obesity, respectively. Never smoking and high levels of physical activity reduced the risks of dying in those
with and without a history of CVD, but normal weight did not. Never-smoking was associated with the
largest gains in total life expectancy (4.3 years, men, 4.1 years, women) and CVD-free life expectancy (3.8
and 3.4 years, respectively). High levels of physical activity and normal weight were associated with lesser
gains in total life expectancy (3.5 years, men and 3.4 years, women, and 1.3 years, men and 1.0 year women,
respectively), and slightly lesser gains in CVD-free life expectancy (3.0 years, men and 3.1 years, women,
and 3.1 years men and 2.9 years women, respectively). Normal weight was the only behaviour associated
with a reduction in the number of years lived with CVD (1.8 years, men and 1.9 years, women).
Conclusions: Achieving high levels of physical activity, normal weight, and never smoking, are effective
ways to prevent cardiovascular disease and to extend total life expectancy and the number of years lived
free of CVD. Increasing the prevalence of normal weight could further reduce the time spent with CVD
in the population.
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Cardiovascular disease (CVD) is the number one cause of
mortality and morbidity in the world, contributing largely
to health care expenditures, and lost productivity due to
disability and death [1]. The effects of modifiable risk fac-
tors, such as smoking, physical inactivity and overweight
on CVD onset and death are well-established [2-10]. Pro-
moting heart-healthy behaviors is a major strategy to
reduce the development of CVD [11]. It may also reduce
the number of years lived with cardiovascular disease in the
population, but this is not necessarily true. Heart-healthy
behaviors, such as non-smoking and physical activity
reduce mortality not only from CVD but also from other
causes [2,4], and if the same intervention not only delays
cardiovascular disease but also death, the time spent with
cardiovascular disease may decrease or increase [12]. To
prioritise between preventive interventions that promote
heart healthy behaviours, comparable information on the
number of years without and with CVD is needed.
Previous studies suggest that non-smoking [13], normal
weight [14] and high/moderate levels of physical activity
[15] each are associated with a longer CVD-free and total
life expectancy, but to a different extent. The effects on the
number of years lived with cardiovascular disease also
appeared to vary between these behaviours. Normal
weight reduced [14] and never smoking [13] increased the
time spent with cardiovascular disease, whilst physical
activity [15] did not suggest a clear association. However,
there were a number of methodological differences
between the studies so it is unclear to what extent these
results reflect real differences in the potential effects.
We aimed to calculate in a comparable way the effects of
never smoking, normal weight and physical activity in
populations aged 50+ on transitions from no CVD to car-
diovascular disease, no CVD to death, and cardiovascular
disease to death and on their life expectancy and the
number of years lived with and without cardiovascular
disease.
Methods
Data Sources
The Framingham Heart Study consisted of a cohort of
5209 respondents residing in Framingham, Massachu-
setts, between 1948 and 1951. The study included both
men (n = 2336) and women (n = 2873) aged 28 to 62
years. The cohort has been examined biannually for over
50 years. Further description can be found in [16] and on
the FHS website http://www.framinghamheartstudy.org/.
Ethical approval was not required as this study was based
on secondary data analysis.
Study Sample
We split the FHS dataset into three, non-overlapping fol-
low-up intervals of 12 years. We chose 12 years of follow-
up to maximize power and minimize the risks for selec-
tion and reverse causation, which means that lower phys-
ical activity levels, BMI levels, and quitting smoking are
caused by ill health and not the other way around [15,17].
Moreover, information on physical activity was available
for a limited number of exams. The follow-up intervals
started therefore at the exams 4 (1956-1958), 11/12
(1969-1973) and 19/20 (1985-1989). Each interval
started with a measurement of the health behaviors and
confounders (education was only measured once). Using
the pooling of repeated observations method [18], the
three intervals were pooled, yielding a total of 9773 obser-
vation-intervals. The same participant may thus be fol-
lowed during three periods until the event (CVD or death)
occurs or the subject is censored because of competing
events or lost to follow-up (n = 64). Splitting and pooling
of non-overlapping intervals does not affect the number
of events and person-years, but allows updating of health
behavior status and confounders in each interval and cov-
erage of the whole age range of age 50 and over. Persons
below age 50 at follow up (n = 208) were excluded, yield-
ing a total of 9565 observation intervals. Information on
physical activity was missing for 592 observation-inter-
vals. These were not excluded, but grouped into a separate
category as missing physical activity. Information on one
or more other health behaviors was missing for 81 obser-
vation-intervals, on the presence of baseline diseases for
179 observation-intervals and on blood pressure for 1
observation-interval. After excluding those with missing
data (in total 261 observation intervals) we included 4209
participants starting at exam four, 3446 at exam 11/12
and 1649 at exam 19/20 yielding a total of 9304 observa-
tion-intervals from 4634 subjects.
Assessment of physical activity, smoking, and BMI
For physical activity, participants were asked to estimate
how long they spent in a typical day at various levels of
activity: sleeping, resting, or engaged in light, moderate
and heavy physical activity. The reported levels of activity
were weighted based on the estimated oxygen consump-
tion for each activity to reflect metabolic expenditure cor-
respondent to metabolic equivalents (METs). Weights
used were: for sleeping 1, for being sedentary 1.1, for light
activity 1.5, for moderate activity 2.4 and for heavy activ-
ity 5. Finally, a daily physical activity score was calculated
by adding the sum of the weighted hours for each level of
activity. The minimum possible score is 24 for a partici-
pant sleeping 24 hours/day. Further detail on the assess-
ment of physical activity and calculation of the daily
physical activity score can be found elsewhere [15,19].
Based on tertiles of the physical activity score, we grouped
the participants into three levels: low (<30), moderate
(30-33) and high (>33) physical activity level[15,17]
For smoking, subjects were classified as never, ever and
current smoker at the start of each of the three follow-up
periods [13].Page 2 of 9
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<18.5 kg/m2 for underweight, 18.5 ≤ BMI<25 kg/m2 for
normal weight, 25 ≤ BMI<30 kg/m2 for overweight, and ≥
30 kg/m2 for obesity [20]. We separated those with under-
weight from the normal weight group to avoid reverse
causation, but will not present results for this small group.
Assessment of Cardiovascular Disease
The primary outcome of our study is first incident or fatal
cardiovascular disease and death. Cardiovascular disease
included coronary heart disease (angina, coronary insuffi-
ciency, myocardial infarction and sudden or not sudden
death as consequence of coronary disease), congestive
heart failure, stroke, transient ischemic attack and inter-
mittent claudication. A panel of three physicians evalu-
ated all events; agreement of all three was required. For all
events (incidence of CVD and death) exact dates were
recorded. More detail on the evaluation of outcomes in
the Framingham Heart Study is available elsewhere [21]
Measurement of potential confounders and intermediates
Potential confounders considered were: age, sex, educa-
tion (eight grade or less/higher than eighth grade), marital
status (single/married/widowed/separated or divorced),
co-morbidity at each baseline (having at least one of the
following diseases: cancer, diabetes, left ventricular hyper-
trophy, arthritis, ankle edema or any pulmonary disease)
and the exam at the start of follow-up (exam 4, 11/12 or
19/20). The latter was included to correct for potential
cohort and period effects, since the participants could
belong to three different periods of follow-up and differ-
ent birth cohorts. Depending on the health behaviour of
interest, smoking, physical activity, BMI and blood pres-
sure (hypotension, normotension, pre-hypertension, and
hypertension) were considered as confounders. Normo-
tension was defined as systolic blood pressure (SBP)
between 90 and 120 mmHg and diastolic blood pressure
(DBP) between 50 and 80 mmHg, pre-hypertension as
SBP between 120 and 139 mmHg and DBP between 80
and 89 mmHg and hypertension as SBP above 140 or DBP
greater or equal than 90 mmHg and hypotension as SBP
below 90 and DBP below 50 [22]. Data on cholesterol lev-
els were not available for more than 40% of the partici-
pants and was therefore not included.
Data Analysis
We built population-based multi-radix multi state life
tables [23] with three states (free of CVD, history of CVD
and death) to assess associations between each of the
three heart health behaviors (smoking, physical activity,
and BMI), and life expectancy with and without CVD at
age 50. We first derived overall transition rates by single
year of age and sex, irrespective of risk factor status, for
three transitions ('no history of CVD' to 'history of CVD',
or to 'death' and from 'history of CVD' to 'death') which
together determine life expectancy with(out) CVD. Next
we calculated hazard ratios (HRs) to assess the relation
between the risk factor status and the three transitions.
Finally these HRs, in combination with the overall transi-
tion rates and risk-factor prevalence were used in a multi-
state life table to calculate life expectancy with and with-
out CVD at age 50 by risk factor level.
The overall transition rates were specific for age and sex.
Prevalence of health behavior level was assessed by sex,
10-year age groups, and separately for subjects with and
without cardiovascular disease.
Overall age-specific transition rates were calculated with
Poisson regression using the Gompertz distribution to
obtain smoothed age-specific rates. HRs adjusted for sex,
age, and potential confounders were also based on this
Poisson regression model. We assumed proportional haz-
ards, unless the log-likelihood ratio test showed a signifi-
cant improvement of the fit of the model (significance
level 5%) when interactions with age (50 to 70 years vs.
older than 70), or sex were included. This was only true
for the sex-smoking interaction for the transition from
non-CVD to CVD. Three final models were selected. One
model adjusted for only age and sex, the second model
adjusted additionally for confounders, and the third
model also for intermediates. Co-morbidity and exam at
the start of follow up were included as confounders. Edu-
cation and marital status were not included, as these fac-
tors did not substantially alter the HRs of the health
behaviours. Additionally, physical activity, BMI and
blood pressure were included as confounders for smok-
ing, and smoking as confounder for physical activity and
BMI. We did not include BMI as confounder for physical
activity and vice versa, as these factors can act as both con-
founders and/or intermediate factors in the causal path-
way and correcting would then imply ignoring part of
their causal effect. Nonetheless, correcting for BMI in
assessing the effects of physical activity, or vise versa,
hardly changed the HRs of BMI and physical activity,
respectively. The same was true for correcting for blood
pressure in assessing the effects of non-smoking.
Blood pressure was considered as an intermediate factor
for both BMI and physical activity as blood pressure is in
the causal chain between the BMI/physical activity and
cardiovascular disease and death [14].
We re-ran all analyses excluding the first two years of fol-
low-up to avoid reverse causation, but as this hardly
affected the HRs they were not excluded in the main anal-
yses.
We then built multi-state life tables based on the HRs,
overall transition rates and prevalence of the specificPage 3 of 9
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tory of CVD and history of CVD. We used HRs adjusted
for age, sex and potential confounders. The life tables
started at age 50 and closed at age 100. No back flows
were allowed and only the first entry into a state was con-
sidered. Similar calculations have been described previ-
ously [15,17]. All statistical analyses were done using
STATA version 8.2 for Windows (Stata Corporation, col-
lege station TX, USA, 2003). Life tables were calculated in
Excel, worksheets are available upon request. We calcu-
lated confidence intervals for all life expectancies and
their differences using Monte Carlo simulation (paramet-
ric bootstrapping) [24] with @RISK (Anonymous 2000;
MathSoft Inc 1999, http://www.palisade.com/RISK/),
10000 runs.
Results
Baseline characteristics
The mean age of the pooled study population was 62
years, 57% were women, 76% were married and 74% had
an educational level higher than 8th grade (Table 1). This
pooled study population is the aggregate of observations
in three intervals, which together capture all ages in the
population aged 50 and over. The second and third period
included increasingly older ages and more recent years,
and thus included a higher percentage of women, unmar-
ried (widowed) persons, persons with co-morbidity and
lower percentage of smokers as compared to the first one.
Risk of Cardiovascular Disease and Death
Onset of cardiovascular disease
High physical activity, never smoking (only men), and
normal weight were each associated with 20-40% lower
risks of developing CVD (Table 2) as compared to low
physical activity, current smoking and obesity. Over-
weight and former smoking were also associated with
lower risks of CVD compared to obesity and current
smoking. The effects of smoking differed significantly by
sex, for women the effects were of a smaller magnitude
and non-significant. Adjustment for confounders and
intermediates generally slightly attenuated the effects.
Table 1: Baseline characteristics of the Framingham Heart Study population in exam 4, exam 11/12, exam 19/20 and in the pooled 
dataset
Exam 4 Exam 11/12 Exam 19/20 Pooled
Characteristics N = 4209 N = 3446 N = 1946 N = 9304*
Age, mean (SD), y 50.5(8.2) 63.7 (7.9) 74.9 (6.3) 59.6(12.1)
Women, No. (%) 2346 (56) 1990 (58) 1004 (61) 5340 (57)
Marital status, No. (%)a
Single 366 (9) 244 (7) 121 (7) 731 (8)
Married 3589 (85) 2449 (73) 945 (57) 6983 (76)
Widowed 167 (4) 564 (17) 534 (32) 1265 (14)
Divorced/Separated 87 (2) 93 (3) 49 (3) 229 (2)
Education, No. (%)b
8th grade or less 1178 (29) 847 (25) 339 (21) 2364 (26)
Higher than 8th grade 2942 (71) 2500 (75) 1264 (79) 6706 (74)
Pa level, No. (%)
Low 1294 (31) 979 (28) 446 (27) 2719 (29)
Moderate 1611 (38) 1155 (34) 426 (26) 3192 (34)
High 1017 (24) 1121 (33) 734 (45) 2872 (31)
Missing 287 (7) 191 (6) 43 (3) 521 (6)
Smoking Status, No. (%)
Never smoker 1521 (36) 1176 (34) 604 (37) 3301 (35)
Former smoker 466 (11) 1055 (31) 807 (49) 2328 (25)
Current smoker 2222 (53) 1215 (35) 238 (14) 3675 (39)
Any co-morbidity†, No. (%) 1351 (32) 1471 (43) 1190 (72) 4012 (43)
BMI‡, mean (SD), kg/m2 25.9 (4.1) 26.1 (4.2) 26.4 (4.5) 26.1 (4.2)
SBP, mean (SD), mmHg 133.9 (22.9) 141.3 (22.2) 143.7 (22.1) 138.3 (22.7)
DBP, mean (SD), mmHg 83.7 (12.2) 97.2 (29.8) 75.9 (10.9) 87.3 (22.0)
Abbreviations: Pa, Physical activity; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.
*Pooled observation intervals of 4634 subjects alive and with no missing data on baseline chronic diseases and on smoking, hypertension and BMI.
† Any co-morbidity: cancer (n = 447 in pooled population, diabetes mellitus (n = 536), left ventricular hypertrophy (n=536), arthritis (n=2088), 
ankle edema (n=1168) or pulmonary disease (n = 755)
‡ Body Mass Index, calculated as BMI = weight in kg/height2 in m2
aBased on: 4109 (exam 4), 3350 (exam 11/12), 1649 (exam 19/200) and 9208 subjects (pooled dataset).
bBased on: 4120 (exam 4), 3347 (exam 11/12), 1600 (exam 19/200) and 9070 subjects (pooled dataset).Page 4 of 9
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Table 2: Hazard ratios for the different transitions for men and women, based on the Framingham Heart Study based on the pooled dataset
No CVD to CVD No CVD to death CVD to death
Number of 
events
1698 739 1465
Person years 65685.47 65685.47 18139.31
Model 1
HR 
(95% CI)
Adj. for 
age+sex
Model 2
HR 
(95% CI)
+ confounders*
Model 3
HR 
(95% CI)
+ intermediates†
Model 1
HR 
(95% CI)
Adj. for 
age+sex
Model 2
HR 
(95% CI)
+ confounders*
Model 3
HR 
(95% CI)
+ 
intermediates†
Model 1
HR 
(95% CI)
Adj. for 
age+sex
Model 2
HR 
(95% CI)
+ confounders*
Model 3
HR 
(95% CI)
+ 
intermediates†
Physical activity
Low 1 1 1 1 1 1 1 1
Mod 0.93 (0.82;1.05) 0.95 (0.84;1.07) 0.98 (0.87;1.10) 0.75 (0.63;0.91) 0.77 (0.64;0.92) 0.78 (0.65;0.93) 0.93 (0.82;1.05) 0.96 (0.85;1.09) 0.98 (0.86;1.11)
High 0.75 (0.66;0.85) 0.78 (069;0.89) 0.81 (0.71;0.92) 0.68 (0.56;0.82) 0.69 (0.57;0.85) 0.71 (0.58;0.86) 0.67 (0.58;0.77) 0.74 (0.64;0.85) 0.76 (0.66;0.87)
Smoking Men
Current 1 1 1 1 1 1 1 1 1
Former 0.74 (0.60;0.91) 0.73 (0.59;0.90) 0.73 (0.59;0.90) 0.54 (0.44;0.66) 0.56 (0.46;0.68) 0.56 (0.46;0.68) 0.76 (0.66;0.88) 0.77 (0.67:0.90) 0.77 (0.67:0.90)
Never 0.66 (0.56;0.77) 0.63 (0.54;0.74) 0.63 (0.54;0.74) 0.67 (0.56;0.81) 0.69 (0.57;0.83) 0.69 (0.57;0.83) 0.73 (0.64;0.83) 0.82 (0.71;0.94) 0.82 (0.71;0.94)
Smoking Women
Current 1 1 1 1 1 1 1 1 1
Former 0.92 (0.78;1.09) 0.83 (0.70;0.99) 0.83 (0.70;0.99) 0.54 (0.44;0.66) 0.56 (0.46;0.68) 0.56 (0.46;0.68) 0.76 (0.66;0.88) 0.77 (0.67:0.90) 0.77 (0.67:0.90)
Never 0.93 (0.76;1.14) 0.89 (0.72;1.08) 0.89 (0.72;1.08) 0.67 (0.56;0.81) 0.69 (0.57;0.83) 0.69 (0.57;0.83) 0.73 (0.64;0.83) 0.82 (0.71;0.94) 0.82 (0.71;0.94)
BMI
Obese 1 1 1 1 1 1 1 1
Overweight 0.86 (0.75;0.98) 0.86 (0.75;0.98) 0.92 (0.81;1.05) 0.81 (0.65;1.01) 0.80 (0.64;1.00) 0.83 (0.66;1.04)) 0.93 (0.80;1.08) 0.93 (0.80;1.08) 0.96 (0.83;1.11)
Normal weight 0.69 (0.60;0.79) 0.69 (0.59;0.79) 0.79 (0.69;0.92) 0.99 (0.79;1.22) 0.95 (0.76;1.18) 0.99 (0.79:1.23) 1.10 (0.95;1.29) 1.10 (0.94;1.27) 1.13 (0.97;1.31)
*Corrected for (co) morbidity (any of the following diseases: cancer, diabetes mellitus, left ventricular hypertrophy, arthritis, ankle edema or any pulmonary disease), and the start of follow-up 
(exam 4, 11/12 or 19/20). Physical activity is additionally corrected for smoking. Smoking is additionally corrected for physical activity, BMI and hypertension, and BMI is additionally corrected for 
smoking.
† Corrected for (co) morbidity (any of the following diseases: cancer, diabetes mellitus, left ventricular hypertrophy, arthritis, ankle edema or any pulmonary disease), and the start of follow-up 
exam 4, 11/12 or 19/20), and all other health behaviors and blood pressure. For smoking this is the same model as model 2.
BMC Public Health 2009, 9:487 http://www.biomedcentral.com/1471-2458/9/487Only in women adjustment slightly increased the effects
of smoking (Table 2).
Death in persons without CVD
The risk of dying in those without a history of CVD was
30% lower among persons with high physical activity lev-
els and never smokers, as compared to persons with low
levels of physical activity and current smokers (Table 2).
Moderate physical activity and former smoking were also
associated with reductions in the risk of mortality. Adjust-
ment for confounders and intermediates slightly attenu-
ated the effects (Table 2). Normal weight and overweight
were not associated with lower mortality risks as com-
pared to obesity.
Death in persons with CVD
The risk of dying once cardiovascular disease is present
was lower among never smokers (men) and those with
high levels of physical activity (Table 2). Adjustment for
confounders and other health behaviours slightly attenu-
ated the effects. Having normal weight or overweight as
compared to being obese, and moderate physical activity
as compared to low, did not significantly alter the mortal-
ity risks once CVD is present.
Life Expectancy with and without cardiovascular disease
Never smokers, persons with high physical activity, and
persons with normal weight had higher total and CVD-
free life expectancy than current smokers, persons with
low physical activity and obese persons, respectively, but
the magnitude of the effects differed (Table 3). Never
smoking was associated with the largest gains in total life
expectancy (4.3 years in men and 4.1 years in women),
followed by high physical activity (3.5 and 3.4 years,
respectively), and finally by normal weight (1.3 and 1.0
years respectively). The largest gains in CVD-free life
expectancy were also found for never smoking (3.8 and
3.4 years, respectively) although differences were only
slightly larger than for high physical activity and normal
weight. Gains in CVD-free life expectancy were similar for
high physical activity (3.0 years, 3.1 years, respectively)
and normal weight (3.1 and 2.9 years, respectively).
Former smokers, persons with moderate physical activity
and persons with overweight also had higher total and
Table 3: Total life expectancy (total LE), CVD-free life expectancy (LE free of CVD) and life expectancy with CVD (LE with CVD), and 
difference, in Years at Age 50, men and women
Total LE (yrs) Dif Total LE 
(yrs)
LE free of CVD 
(yrs)
Dif LE free of 
CVD (yrs)
LE with CVD 
(yrs)
Dif LE with CVD 
(yrs)
Men
Physical activity†
Low 26.4 (25.7;27.3) Ref 19.7 (18.9;20.6) Ref 6.7 (6.2;7.3) Ref
Moderate 27.7 (26.8;28.8) 1.3 (0.3;3.2) 20.8 (19.7;22.0) 1.1 (0.0;2.2) 6.9 (6.2;7.7) 0.2 (-0.6;0.9)
High 30.0 (29.0;31.0) 3.5 (2.5;4.6) 22.8 (21.7;23.9) 3.0 (1.8;4.3) 7.2 (6.5;8.1) 0.5 (-0.3;1.4)
Smoking*
Never 29.7 (28.6;30.7) 4.3 (3.0;5.5) 22.6 (21.3;24.0) 3.8(2.1;5.5) 7.0(6.2;7.8) 0.4 (-0.6;1.5)
Former 29.4 (28.2;30.5) 4.0 (2.1;5.6) 23.3 (21.7;25.0) 4.5(2.0;6.8) 6.0 (5.2;6.9) -0.6 (-2.0;0.9)
Current 25.4 (24.4;26.4) Ref 18.8(17.8;20.0) Ref 6.6 (5.8;7.4) Ref
BMI†
Normal 28.1 (27.4;28.9) 1.3 (0.2;2.5) 22.1 (17.7;20.4) 3.1(1.9;4.4) 6.0(5.5;6.5) -1.8 (-2.8;-0.9)
Overweight 28.5 (27.7;29.3) 1.6 (0.3;3.1) 20.8 (19.9;21.6) 1.7 (0.2;3.3) 7.7(7.1;8.4) -0.1 (-1.3;1.1)
Obesity 26.8 (25.6;28.1) Ref 19.0 (17.7;20.4) Ref 7.8(6.9;8.8) Ref
Women
Physical activity†
Low 32.7 (31.9;33.5) Ref 26.3 (25.5;27.1) Ref 6.4 (5.9;7.0) Ref
Moderate 34.1 (33.2;35.1) 1.5 (0.5;2.5) 27.6 (26.6;28.7) 1.3 (0.2;2.4) 6.6 (5.9;7.3) 0.2(-0.6;0.9)
High 36.1 (35.0;37.2) 3.4 (2.3;4.5) 29.4 (28.2;30.6) 3.1 (1.9;4.3) 6.7 (5.9;7.5) 0.3 (-0.5;1.1)
Smoking*
Never 34.5 (33.9;35.2) 4.1(3.1;5.2) 28.1 (27.5;28.8) 3.4(2.7;4.1) 6.3 (5.9;6.8) 0.7 (0.2;1.3)
Former 33.2 (32.2;34.2) 2.8 (1.3;4.3) 27.0 (26.1;27.8) 2.2 (1.2;3.3) 6.2 (5.7;6.8) 0.6 (-0.2;1.4)
Current 30.4 (29.3;31.5) Ref 24.7 (23.9;25.7) Ref 5.6 (5.0;6.3) Ref
BMI†
Normal 33.8 (33.1;34.6) 1.0 (-0.2;2.2) 28.2 (27.4;29.0) 2.9(1.6;4.2) 5.6 (5.1;6.1) -1.9 (-2.9;-1.0)
Overweight 34.5 (33.7;35.4) 1.7(0.2;2.3) 27.1 (26.22;28.1) 1.9 (0.3;3.5) 7.4 (6.7;8.1) -0.2 (-1.5;1.0)
Obesity 32.8 (31.6;34.1) Ref 25.2 (24.0;26.5) Ref 7.6 (6.7;8.6) Ref
† Corrected for (co) morbidity (any of the following diseases: cancer, diabetes mellitus, left ventricular hypertrophy, arthritis, ankle edema or any 
pulmonary disease), and the start of follow-up (exam 4, 11/12 or 19/20), and smoking
*Corrected for (co) morbidity (any of the following diseases: cancer, diabetes mellitus, left ventricular hypertrophy, arthritis, ankle edema or any 
pulmonary disease), and the start of follow-up (exam 4, 11/12 or 19/20), physical activity, BMI and blood pressure.Page 6 of 9
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with low physical activity and obese persons, but gener-
ally the differences were smaller than in the groups with
the healthiest behaviours (Table 3).
Normal weight was the only heart-healthy behavior asso-
ciated with a decrease in the number of years with CVD
(1.8 years (men) and 1.9 years (women)) (Table 3). In
contrast, women who never smoked spent 0.7 more years
with CVD than current smokers.
Discussion
Never smoking, high levels of physical activity, and nor-
mal weight at age 50 and over appears to be not only asso-
ciated with increases in total life expectancy, but also with
a greater number of years lived free of CVD. The effects on
total life expectancy (both sexes) and years lived free of
CVD (men) appeared greatest for never smoking;
although for women the increase in years free of CVD dif-
fered less between the three health hearty behaviors. Nor-
mal weight was the only behavioral factor in our study
found to also reduce the time lived with CVD.
Never smoking (men), high levels of physical activity, and
normal weight were each associated with lower risks of
developing CVD as compared to low physical activity, cur-
rent smoking and obesity, respectively. Never smoking
and high levels of physical activity also reduced the risks
of dying in those with and without a history of CVD, but
normal weight did not. The greater number of years lived
free of CVD among those with high levels of physical
activity or never smoking is due to their lower incidence
of CVD, in combination with lower mortality without a
history of CVD. The greater number of years free of CVD
and reduction in time lived with CVD among those with
a normal weight is due to lower incidence of CVD, not
being accompanied with a reduction in mortality.
The HRs we found support existing evidence that non-
smoking, physical activity and normal weights reduces
incidence of CVD [2,4,8]. The reductions in mortality
among persons without cardiovascular disease associated
with never smoking and physical activity, are also in line
with documented effects for a large set of fatal diseases,
including respiratory diseases and several cancers [2,4].
Our results also confirm that non-smoking and physical
activity reduces mortality in persons with a history of CVD
[25,26]. The effects of BMI on mortality are more dis-
puted, and appear to depend on the age considered [27].
The lack of a harmful effect of overweight and obesity on
mortality in elderly persons with CVD, is in agreement
with the study of Kalanar-Zadey[28]. It is noteworthy that
our findings on mortality in persons with and without
CVD are not in contrast with existing evidence that obesity
increases overall mortality. In fact, our findings suggests
that higher total mortality among obese persons is mainly
due to higher rates of onset of CVD, which, in combina-
tion with higher mortality risks among persons with CVD,
results in higher total mortality, and not due to worse sur-
vival.
Our results show smaller differences in total life expect-
ancy at age 50 associated with BMI compared to prior
analyses also based on the Framingham Heart Study
[14,29] Additional analyses comparing the studies in
more detail (data available on request) suggested that the
majority of the difference was explained by the fact that
whilst the current analysis assessed the effect of BMI in a
population age 50 and over and updated BMI informa-
tion every 12 years, the prior analyses assessed BMI only
at age 40-50, and followed this cohort without updating
this information to more recent years and ages. The effects
of BMI on mortality have been shown to be smaller in eld-
erly populations [27]. We found also smaller differences
associated with smoking as compared to prior work based
on the Framingham Heart Study [13], which compared
never and always smokers, instead of never, current and
former smokers in the present study.
Some limitations of our study must be considered. This is
a life table analysis based on a prospective observational
study where no intervention was performed. Therefore it
has the inherent weaknesses of all cohort studies and lacks
the strength of causality that randomized trials could
offer. Reverse causation, which means that lower physical
activity levels, BMI levels, and quitting smoking are
caused by ill health and not the other way around, is an
important issue to consider since it could introduce bias
in the evaluation of the effect of these health behaviors.
While owing to the longitudinal design we fulfill the tem-
porality criteria of Bradford and Hill [30] that the effect
(CVD onset or death) has to occur after the cause
(unhealthy behavior), we can not rule out that the health
behavior is affected by the health of the individual. Differ-
ent approaches exist to reduce the effect of reverse causa-
tion but there is no method to eliminate it completely. To
correct for reverse causation we adjusted our analyses for
co-morbidities at baseline instead of excluding the sub-
jects with disease at the start of follow-up, since we are
interested in the effect of health behaviors in the general
elderly population and not in selected healthy popula-
tions. Finally we examined whether excluding the first two
years of follow up did reduce the HRs, but found minimal
effect (data not shown).
Another limitation is that during the Framingham Heart
Study, physical activity and smoking were evaluated by
self-report, which might be affected by recall bias. In con-
trast height and weight were measured in the study. Dif-
ferences in measurement of these behaviors wouldPage 7 of 9
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affects the transitions differently (e.g. affect transition
from cardiovascular disease to death, but not from non-
CVD to cardiovascular disease, or death). However, mis-
classification, if present, is likely to be non-differential
and to affect each transition similarly.
Participants included in the FHS were mainly white; there-
fore, our results may not apply to other ethnic groups. Fur-
thermore, the historical character of the FHS, limits the
extrapolation of findings to today's populations. None-
theless by focusing on those over age 50, and updating
BMI, smoking and physical activity information every 12
years, we have automatically put more weight on contem-
porary data (as older age in the cohort means more recent
years). Life expectancy at age 50 in our study is very simi-
lar to the life expectancy at age 50 in the US in 2000-2004
(life expectancy at age 50: men: FHS: 27.3, US 28.4;
women: 33.7 and 32.2 years respectively)[31]. Also, our
study focuses on comparisons between different risk fac-
tor categories (e.g. normal weight vs. obesity).
The key strengths of our study include using a well-organ-
ized historic cohort that has been followed biannually for
decades (we used 36 years), and provides upgraded infor-
mation on health behaviours, covariates and outcomes.
Further, this is the first comparative life table analysis of
the effects of the main heart-healthy behaviours on life
expectancy and life expectancy with and without CVD.
Conclusion
Our study suggests that interventions increasing popula-
tion levels of physical activity, non-smoking, and normal
weight are an effective way to reduce the incidence of car-
diovascular disease, postpone mortality and to extend
both total life expectancy and the duration of life lived
free of CVD. Whilst trends in non-smoking are moving in
the right direction, the associated benefits in cardiovascu-
lar disease prevention run the risk of being obscured by
reverse trends in the prevalence of obesity and physical
inactivity [32]. If obesity levels continue to rise we would
expect the years lived with cardiovascular disease in the
population to increase, regardless of any advances in non-
smoking and physical activity prevalence.
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